Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (980)	2/4/2000 6:45:00 AM
From: Mike McFarland	Respond to of 4474

Quantitative advantage of bundled activators {Sorry if I am repeating something that has already been pointed out, my skull is month thick window, the light just now getting through.} Went thru "A General Strategy..." and ran the highlighter over this: The simplest explanation for why bundled activators are so much more effective is that there is a threshold requirement for the number of activators that must be delivered to a promoter before transcription can be initiated. (example) and ...we have developed an alternative tetramerization domain of human origin that should be minimally immunogenic (unpublished data). Is this the same Ariad whose shareprice was giving me fits last summer? Of course the manuscript was submitted April 1999, this is not something that they just cooked up these past few months.